Hot Investor Mandate: Family Office Fund Invests in North American Companies in the Intersection of Technology of Life Science, Such as AI-Enabled Drug Discovery Platforms

24 Aug

A new family office fund of a successful hedge fund manager focused on private investments has multiple offices in the US. Due to the single LP structure of the fund, it can be very flexible in terms of investment size and stage. The firm is open to working with companies in the seed, series A, and series B stage with the majority of investments falling in the $500k-2.5M range. The firm also has the ability to allocate $5M or more in situations where they find the opportunity particularly compelling. The firm is capable of both acting as a lead and co-investor, and is primarily focused on companies throughout North America but has exposure to Europe and Asia as well.

The firm has a focus on vertically integrated platforms and software/”software x hardware” systems. Specifically, the firm is interested in AI-enabled drug discovery platforms, lab automation, diagnostics and data collection, and clinical trials management software. The firm is generally agnostic in terms of both stage of development and indication area but is most interested in early stage, highly innovative biotech companies.

The firm is looking for privately held companies with experienced management teams and a product/service with a large addressable market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a comment